J&J Stresses Data Comparison In Push For Top Interventional Cardiology Spot
This article was originally published in The Gray Sheet
Executive Summary
Price premiums and increased procedures related to drug-coated stents are expected to more than double the worldwide interventional cardiology market to $9.2 bil. over the next six years, Johnson & Johnson/Cordis predicts.
You may also be interested in...
SIRIUS Cost Data Suggests Higher Inpatient Payment Level For Eluting Stents
Cost-effectiveness data collected by Johnson & Johnson/Cordis from trials of its Cypher sirolimus-eluting coronary stent will justify assigning the device to a new diagnosis-related group (DRG) in time for the expected 2003 U.S. launch, according to Cordis
SIRIUS Cost Data Suggests Higher Inpatient Payment Level For Eluting Stents
Cost-effectiveness data collected by Johnson & Johnson/Cordis from trials of its Cypher sirolimus-eluting coronary stent will justify assigning the device to a new diagnosis-related group (DRG) in time for the expected 2003 U.S. launch, according to Cordis
Novoste Looking For “Deal-Maker” As CEO Hawkins Moves To Medtronic
Novoste will shift focus from leveraging core technologies and building a sales infrastructure to diversification and growth following the departure of CEO and President Bill Hawkins in mid-January to head Medtronic's vascular unit, Medtronic AVE